| http://www.w3.org/ns/prov#value | - Instead, she describes it as ???only a partial antidote for the systemic challenges facing the agency,??? which critics have seen as including the FDA???s continued reliance on industry experts and its much-maligned monitoring of adverse drug effects.
|
